Cargando…

A Radiobrominated Tyrosine Kinase Inhibitor for EGFR with L858R/T790M Mutations in Lung Carcinoma

Activating double mutations L858R/T790M in the epidermal growth factor receptor (EGFR) region are often observed as the cause of resistance to tyrosine kinase inhibitors (TKIs). Third-generation EGFR-TKIs, such as osimertinib and rociletinib (CO-1686), was developed to target such resistance mutatio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fawwaz, Muammar, Mishiro, Kenji, Nishii, Ryuichi, Makino, Akira, Kiyono, Yasushi, Shiba, Kazuhiro, Kinuya, Seigo, Ogawa, Kazuma
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7998589/ https://www.ncbi.nlm.nih.gov/pubmed/33809064 http://dx.doi.org/10.3390/ph14030256

Ejemplares similares

Synthesis and Fundamental Evaluation of Radioiodinated Rociletinib (CO-1686) as a Probe to Lung Cancer with L858R/T790M Mutations of Epidermal Growth Factor Receptor (EGFR)
por: Fawwaz, Muammar, et al.
Publicado: (2020)

Radiobrominated benzimidazole-quinoline derivatives as Platelet-derived growth factor receptor beta (PDGFRβ) imaging probes
por: Effendi, Nurmaya, et al.
Publicado: (2018)

Development of Radiogallium-Labeled Peptides for Platelet-Derived Growth Factor Receptor β (PDGFRβ) Imaging: Influence of Different Linkers
por: Effendi, Nurmaya, et al.
Publicado: (2020)

Synthesis and Evaluation of a Dimeric RGD Peptide as a Preliminary Study for Radiotheranostics with Radiohalogens
por: Echigo, Hiroaki, et al.
Publicado: (2021)

Decreasing undesirable absorbed radiation to the intestine after administration of radium-223 dichloride for treatment of bone metastases
por: Ogawa, Kazuma, et al.
Publicado: (2020)

Synthesis and evaluation of radiogallium-labeled long-chain fatty acid derivatives as myocardial metabolic imaging agents
por: Effendi, Nurmaya, et al.
Publicado: (2021)

Recruitment of hexahydroquinoline as anticancer scaffold targeting inhibition of wild and mutants EGFR (EGFR(WT), EGFR(T790M), and EGFR(L858R))
por: Abo Al-Hamd, Mahmoud G., et al.
Publicado: (2023)

Simultaneous Detection of the T790M and L858R Mutations in the EGFR Gene by Oligoribonucleotide Interference-PCR
por: Baba, Keisuke, et al.
Publicado: (2019)

Differential MicroRNA Expression between EGFR T790M and L858R Mutated Lung Cancer
por: Kim, Ji Yeon, et al.
Publicado: (2018)

Quinoxalinones as A Novel Inhibitor Scaffold for EGFR (L858R/T790M/C797S) Tyrosine Kinase: Molecular Docking, Biological Evaluations, and Computational Insights
por: Suriya, Utid, et al.
Publicado: (2022)

Unusual metachronous lung adenocarcinomas harboring EGFR L858R/T790M mutations: A case report
por: Pei, Guotian, et al.
Publicado: (2020)

Gossypol Inhibits Non-small Cell Lung Cancer Cells Proliferation by Targeting EGFR(L858R/T790M)
por: Wang, Yuwei, et al.
Publicado: (2018)

Design and Synthesis of New Hydantoin Acetanilide Derivatives as Anti-NSCLC Targeting EGFR(L858R/T790M) Mutations
por: Hassanin, Moamen A., et al.
Publicado: (2022)

Structure-activity exploration of a small-molecule allosteric inhibitor of T790M/L858R double mutant EGFR
por: Foschi, Francesca, et al.
Publicado: (2022)

Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells
por: Wu, Hong, et al.
Publicado: (2015)

Transtinib, a potent tyrosine kinase inhibitor inhibits L858R/T790M mutant NSCLC cell lines and xenografts
por: Hu, Peng, et al.
Publicado: (2016)

YL143, a novel mutant selective irreversible EGFR inhibitor, overcomes EGFR(L858R, T790M)‐mutant resistance in vitro and in vivo
por: Zhang, Zhang, et al.
Publicado: (2018)

Afatinib overcoming resistance to icotinib and osimertinib in NSCLC with leptomeningeal metastasis in patients with acquired EGFR L858R/T790M or L858R/S768I mutations: Two case reports
por: Li, Guangrui, et al.
Publicado: (2023)

Wighteone exhibits an antitumor effect against EGFR L858R/T790M mutation non-small cell lung cancer
por: Sun, Peiyuan, et al.
Publicado: (2021)

Deciphering the molecular mechanism of enhanced tumor activity of the EGFR variant T790M/L858R using melanoma cell lines
por: Shao, Hanshuang, et al.
Publicado: (2023)

Ferumoxytol and CpG oligodeoxynucleotide 2395 synergistically enhance antitumor activity of macrophages against NSCLC with EGFR(L858R/T790M) mutation
por: Wang, Guoqun, et al.
Publicado: (2019)

Evaluation of Ga-DOTA-(D-Asp)(n) as bone imaging agents: D-aspartic acid peptides as carriers to bone
por: Ogawa, Kazuma, et al.
Publicado: (2017)

AI-Based Drug Discovery of TKIs Targeting L858R/T790M/C797S-Mutant EGFR in Non-small Cell Lung Cancer
por: Choi, Geunho, et al.
Publicado: (2021)

Leptomeningeal Metastatic L858R EGFR-mutant Lung Cancer: Prompt Response to Osimertinib in the Absence of T790M-mutation and Effective Subsequent Pulsed Erlotinib
por: Kanbour, Aladdin, et al.
Publicado: (2022)

Overcoming EGFR T790M-based Tyrosine Kinase Inhibitor Resistance with an Allele-specific DNAzyme
por: Lai, Wei-Yun, et al.
Publicado: (2014)

In Vivo Differences between Two Optical Isomers of Radioiodinated o-iodo-trans-decalinvesamicol for Use as a Radioligand for the Vesicular Acetylcholine Transporter
por: Uno, Izumi, et al.
Publicado: (2016)

In silico design of EGFR(L858R/T790M/C797S) inhibitors via 3D-QSAR, molecular docking, ADMET properties and molecular dynamics simulations
por: Hadni, Hanine, et al.
Publicado: (2022)

Heterogeneity among tumors with acquired resistance to EGFR tyrosine kinase inhibitors harboring EGFR‐T790M mutation in non‐small cell lung cancer cells
por: Katayama, Yuki, et al.
Publicado: (2022)

Compound 15c, a Novel Dual Inhibitor of EGFR(L858R/T790M) and FGFR1, Efficiently Overcomes Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Resistance of Non-Small-Cell Lung Cancers
por: Chen, Gaozhi, et al.
Publicado: (2020)

Effect of postconditioning on dynamic expression of tenascin-C and left ventricular remodeling after myocardial ischemia and reperfusion
por: Taki, Junichi, et al.
Publicado: (2015)

Significance of micro-EGFR T790M mutations on EGFR-tyrosine kinase inhibitor efficacy in non-small cell lung cancer
por: Masuda, Takeshi, et al.
Publicado: (2023)

Computational identification of natural product inhibitors against EGFR double mutant (T790M/L858R) by integrating ADMET, machine learning, molecular docking and a dynamics approach
por: Agarwal, Subhash M., et al.
Publicado: (2022)

Design, synthesis, and biological evaluation of pyrido[2,3-d]pyrimidine and thieno[2,3-d]pyrimidine derivatives as novel EGFR(L858R/T790M) inhibitors
por: Fu, Jianfang, et al.
Publicado: (2023)

De Novo T790M Mutation in an L858R Epidermal Growth Factor Receptor Mutant-Associated Lung Adenocarcinoma
por: Fujiwara, Takumi, et al.
Publicado: (2020)

Emerging a Novel VOPP1-EGFR Fusion Coexistent With T790M as an Acquired Resistance Mechanism to Prior Icotinib and Sensitive to Osimertinib in a Patient With EGFR L858R Lung Adenocarcinoma: A Case Report
por: Wang, Xia, et al.
Publicado: (2021)

MLH1 V384D polymorphism associates with poor response to EGFR tyrosine kinase inhibitors in patients with EGFR L858R-positive lung adenocarcinoma
por: Chiu, Chao-Hua, et al.
Publicado: (2015)

Optimizing Sequential Treatment With EGFR Tyrosine Kinase Inhibitor With a Simulation of the T790M Mutation Rate in EGFR–Mutated Lung Cancer
por: Haratake, Naoki, et al.
Publicado: (2020)

Effective treatment of pulmonary adenocarcinoma harboring triple EGFR mutations of L858R, T790M, and cis-C797S by osimertinib, bevacizumab, and brigatinib combination therapy: a case report
por: Zhao, Jing, et al.
Publicado: (2018)

EGFR tyrosine kinase inhibitor HS-10182 increases radiation sensitivity in non-small cell lung cancers with EGFR T790M mutation
por: Chen, Yang, et al.
Publicado: (2018)

Triple targeting of mutant EGFR(L858R/T790M), COX-2, and 15-LOX: design and synthesis of novel quinazolinone tethered phenyl urea derivatives for anti-inflammatory and anticancer evaluation
por: Kothayer, Hend, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ha0tlgkojqoh0bd9t8evs1766r